FDA advisers vote to oppose Pfizer/BioNTech COVID-19 vaccine booster
Tweet
Share
E-mail
FILE PHOTO: A vial labelled with the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine is seen in this illustration picture taken March 19, 2021. REUTERS/Dado Ruvic/Illustration
(Reuters) - A panel of outside advisers to the U.S. Food and Drug Administration on Friday voted against approval of a booster dose of the Pfizer Inc/BioNTech SE COVID-19 vaccine for people aged 16 and older.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Leslie Adler)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA approves Scholar Rock's ISEMBYLD for spinal muscular atrophy
- FDA approves Pharming's Joenja for children ages 4 to 11 with APDS
- Lyell shifts LYL273 trial timeline, eyes 2027 FDA meeting
Create E-mail Alert Related Categories
FDA, General News, ReutersRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
